• Amsterdam-based biotech LinXis raised nearly €5 million from ROM InWest and existing shareholders to fund its first clinical study.
• The financing extends an earlier €15 million round that funded development of its Fibrobody technology.
• Fibrobodies are small proteins designed to target fibrosis-causing cells for drug delivery or imaging while sparing healthy cells.
• The trial will assess whether Fibrobodies reach fibrosis-causing cells in patients with liver, lung or kidney fibrosis.
• Ethics clearance was granted in August 2026; initial results are expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ROM InWest BV published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.